References

Download Assets

  1. Abdelmagid OY, Larson L, Payne L, et al. Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus, and distemper virus experimental challenges. Vet Ther 2004;5(3):173–86.
  2. Decaro N, Buonavoglia C, Barrs VR. Canine parvovirus vaccination and immunisation failures: are we far from disease eradication? Vet Microbiol 2020;247:108760.
  3. Decaro N, Crescenzo G, Desario C, et al. Long-term viraemia and fecal shedding in pups after modified-live canine parvovirus vaccination. Vaccine 2014;32(30):3850–3.
  4. Day MJ. Companion animal vaccines. In: Ettinger SJ, Feldman EC, eds. Textbook of veterinary internal medicine. 8th ed. St. Louis: Elsevier- Saunders; 2017:895.
  5. Francis MJ. Recent advances in vaccine technology. Vet Clin North Am Small Anim Pract 2018;48(2):231–41.
  6. Gaskell RM, Dawson S, Radford AD. Duration of immunity (DOI) – the regulatory issues. Vet Microbiol 2006;117(1):80–5.
  7. Gill M, Srinivas J, Morozov I, et al. Three-year duration of immunity for canine distemper, adenovirus, and parvovirus after vaccination with a multivalent canine vaccine. Int J Appl Res Vet Med 2004;2(4):227–34.
  8.  Larson LJ, Schultz RD. Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine. Vet Ther 2007;8(4):305–10.
  9. Meeusen ENT, Walker J, Peters A, et al. Current status of veterinary vaccines. Clin Microbiol Rev 2007;20(3):489–510.
  10. Mouzin DE, Lorenzen MJ, Haworth JD, et al. Duration of serologic response to five viral antigens in dogs. J Am Vet Med Assoc 2004;224 (1):55–60.
  11. Schultz RD, Thiel B, Mukhtar E, et al. Age and long-term protective immunity in dogs and cats. J Comp Pathol 2010;142(suppl 1):S102–8.
  12. Miranda C, Thompson G. Canine parvovirus: the worldwide occurrence of antigenic variants. J Gen Virol 2016;97:2043–57.
  13. Decaro N, Buonavoglia C, Barrs VR. Canine parvovirus vaccination and immunisation failures: Are we far from disease eradication? Vet Microbiol 2020;247:108760.
  14. Pollock RV, Carmichael LE. Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination. J Am VetMed Assoc 1982;180:37–42.
  15. Lechner ES, Crawford PC, Levy JK, et al. Prevalence of protective antibody titers for canine distemper virus and canine parvovirus in dogs entering a Florida animal shelter. J Am Vet Med Assoc 2010;236: 1317–21.
  16. Altman KD, Kelman M, Ward MP. Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure? Vet Microbiol 2017;210:8–16.
  17. Kelman M, Barrs VR, Norris JM, et al. Canine parvovirus prevention and prevalence: veterinarian perceptions and behaviors. Prev Vet Med 2020;174:104817.
  18. Bass EP, Gill MA, Beckenhauer WH. Evaluation of a canine adenovirus type 2 strain as a replacement for infectious canine hepatitis vaccine. J Am VetMed Assoc 1980;177(3):234–42.
  19. Hornsey SJ, Philibert H, Godson DL, et al. Canine adenovirus type 1 causing neurological signs in a 5-week-old puppy. BMC Vet Res 2019; 15:418.
  20. Brown CM, Slavinski S, Ettestad P, et al. Compendium of animal rabies prevention and control, 2016. J Am VetMed Assoc 2016;248(5):505–17.
  21. Frana TS, Clough NE, Gatewood DM, et al. Postmarketing surveillance of rabies vaccines for dogs to evaluate safety and efficacy. J Am Vet Med Assoc 2008;232(7):1000–2.
  22. Ma X, Monroe BP, Cleaton, JM, et al. Public Veterinary Medicine: Public Health: Rabies surveillance in the United States during 2018. J Am Vet Med Assoc 2020;256:195-208.
  23. Moore SM. Rabies: Current preventive strategies. Vet Clin North Am Small Anim Pract 2019;49(4):629–41.
  24. Moore MC, Davis RD, Kang Q, et al. Comparison of anamnestic responses to rabies vaccination in dogs and cats with current and outof- date vaccination status. J Am VetMed Assoc 2015;246:205–11.
  25. Murray KO, Holmes KC, Hanlon CA. Rabies in vaccinated dogs and cats in the United States, 1997-2001. J Am Vet Med Assoc 2009;235: 691–5.
  26. Srinivas GB, Walker A, Rippke B. USDA regulatory guidelines and practices for veterinary Leptospira vaccine potency testing. Biologicals 2013;41:298–302.
  27. Wilson S, Stirling C, Thomas A, et al. A new multivalent (DHPPi/L4R) canine combination vaccine prevents infection, shedding and clinical signs following experimental challenge with four Leptospira serovars. Vaccine 2013;31:3131–4.
  28. Eric Klaasen HL, Adler B. Recent advances in canine leptospirosis: focus on vaccine development. Vet Med (Aukl) 2015;6:245–60.
  29. Sonrier CB, Michel V, RuvoeÈn-Clouet N, et al. Evidence of crossprotection within Leptospira interrogans in an experimental model. Vaccine 2001;19:86–94.
  30. Grosenbaugh DA, Pardo MC. Fifteen-month duration of immunity for the serovar Grippotyphosa fraction of a tetravalent canine leptospirosis vaccine. Vet Rec 2018;182:665.
  31. Klaasen HL, Molkenboer MJ, Vrijenhoek MP, et al. Duration of immunity in dogs vaccinated against leptospirosis with a bivalent inactivated vaccine. Vet Microbiol 2003;95:121–32.
  32. Minke JM, Bey R, Tronel JP, et al. Onset and duration of protective immunity against clinical disease and renal carriage in dogs provided by a bi-valent inactivated leptospirosis vaccine. Vet Microbiol 2009;137: 137–45.
  33. Schreiber P, Martin V, Grousson D, et al. One-year duration of immunity in dogs for Leptospira Interrogans serovar Icterohaemorrhagiae after vaccination. Int J Appl Res Vet Med 2012;10:305–10.
  34. Wilson S, Stirling C, Thomas A, et al. Duration of immunity of a multivalent (DHPPi/L4R) canine vaccine against four Leptospira serovars. Vaccine 2013;31:3126–30.
  35. Bouvet J, Cariou C, Valfort W, et al. Efficacy of a multivalent DAPPi- Lmulti canine vaccine against mortality, clinical signs, infection, bacterial excretion, renal carriage and renal lesions caused by Leptospira experimental challenges. Vaccine Rep 2016;6:23–8.
  36. Lee HS, Guptill L, Johnson AJ, et al. Signalment changes in canine leptospirosis between 1970 and 2009. J Vet Intern Med 2014;28:294–9.
  37. Ricardo T, Previtali MA, Signorini M. Meta-analysis of risk factors for canine leptospirosis. Prev Vet Med 2020;181:105037.
  38. Iverson SA, Levy C, Yaglom HD, et al. Clinical, diagnostic, and epidemiological features of a community-wide outbreak of canine leptospirosis in a low-prevalence region (Maricopa County, Arizona). J Am Vet Med Assoc 2021;258:616–29.
  39. Azocar-Aedo L, Monti G. Meta-analyses of factors associated with leptospirosis in domestic dogs. Zoonoses Public Health 2016;63:328–36.
  40. Martin LE, Wiggans KT, Wennogle SA, et al. Vaccine-associated Leptospira antibodies in client-owned dogs. J Vet InternMed 2014;28:789–92.
  41. Kodjo A, Calleja C, Loenser M, et al. A rapid in-clinic test detects acute leptospirosis in dogs with high sensitivity and specificity. Biomed Res Int 2016;2016:3760191.
  42. Lizer J, Grahlmann M, Hapke H, et al. Evaluation of a rapid IgM detection test for diagnosis of acute leptospirosis in dogs. Vet Rec 2017; 180:517.
  43. Midence J, Leutenegger C, Chandler A, et al. Effects of recent Leptospira vaccination on whole blood real-time PCR testing in healthy client-owned dogs. J Vet InternMed 2012;26:149–52.
  44. Stokes W, Srinivas G, McFarland R, et al. Report on the international workshop on alternative methods for Leptospira vaccine potency testing: state of the science and the way forward. Biologicals 2013;41:279–94.
  45. Troia R, Balboni A, Zamagni S, et al. Prospective evaluation of rapid point-of-care tests for the diagnosis of acute leptospirosis in dogs. Vet J 2018;237:37–42.
  46. Mwachui MA, Crump L, Hartskeerl R, et al. Environmental and behavioural determinants of leptospirosis transmission: a systematic review. PLoS Negl Trop Dis 2015;9:e0003843.
  47. Martins G, Penna B, Lilenbaum W. The dog in the transmission of human leptospirosis under tropical conditions: victim or villain? Epidemiol Infect 2012;140:207–8; author reply 208–9.
  48. Major A, Schweighauser A, Francey T. Increasing incidence of canine leptospirosis in Switzerland. Int J Environ Res Public Health 2014;11: 7242–60.
  49. Gay N, Soup e-Gilbert M-E, Goarant C. Though not reservoirs, dogs might transmit Leptospira in New Caledonia. Int J Environ Res Public Health 2014;11:4316–25.
  50. Klaasen HL, van der Veen M, Molkenboer MJ, et al. A novel tetravalent Leptospira bacterin protects against infection and shedding following challenge in dogs. Vet Rec 2013;172:181.
  51. Bouvet J, Lemaitre L, Cariou C, et al. A canine vaccine against Leptospira serovars Icterohaemorrhagiae, Canicola and Grippotyphosa provides cross protection against Leptospira serovar Copenhageni. Vet Immunol Immunopathol 2020;219:109985.
  52. Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed within three days of vaccine administration in dogs. J Am Vet Med Assoc 2005;227:1102–8.
  53. Yao PJ, Stephenson N, Foley JE, et al. Incidence rates and risk factors for owner-reported adverse events following vaccination of dogs that did or did not receive a Leptospira vaccine. J Am Vet Med Assoc 2015; 247:1139–45.
  54. Robbins H. Adverse events in dogs given Leptospira vaccine. Vet Rec 2017;180:257.
  55. Eisen L. Vector competence studies with hard ticks and Borrelia burgdorferi sensu lato spirochetes: a review. Ticks Tick Borne Dis 2020;11:101359.
  56.  O’Bier NS, Hatke AL, Camire AC, et al. Human and veterinary vaccines for Lyme disease. Curr Issues Mol Biol 2021;42:191–222.
  57. Honsberger NA, Six RH, Heinz TJ, et al. Efficacy of sarolaner in the prevention of Borrelia burgdorferi and Anaplasma phagocytophilum transmission from infected Ixodes scapularis to dogs. Vet Parasitol 2016;222:67–72.
  58. Krämer F, Hüsken R, Krüdewagen EM, et al. Prevention of transmission of Borrelia burgdorferi sensu lato and Anaplasma phagocytophilum by Ixodes spp. ticks to dogs treated with the Seresto® collar (imidacloprid10%1 flumethrin 4.5%). Parasitol Res 2020;119:299–315.
  59. Little S, Braff J, Place J, et al. Canine infection with Dirofilaria immitis, Borrelia burgdorferi, Anaplasma spp., and Ehrlichia spp. in the United States, 2013–2019. Parasit Vectors 2021;14:1–16.
  60. Herrin BH, Peregrine AS, Goring J, et al. Canine infection with Borrelia burgdorferi, Dirofilaria immitis, Anaplasma spp. and Ehrlichia spp. in Canada, 2013–2014. Parasit Vectors 2017;10:1–9.
  61. Evason M, Stull JW, Pearl DL, et al. Prevalence of Borrelia burgdorferi, Anaplasma spp., Ehrlichia spp. and Dirofilaria immitis in Canadian dogs, 2008 to 2015: a repeat cross-sectional study. Parasit Vectors 2019;12:64.
  62. Liu Y, Nordone SK, Yabsley MJ, et al. Quantifying the relationship between human Lyme disease and Borrelia burgdorferi exposure in domestic dogs. Geospatial Health 2019;14:111–20.
  63. Littman MP, Gerber B, Goldstein RE, et al. ACVIM consensus update on Lyme borreliosis in dogs and cats. J Vet Intern Med 2018; 32:887–903.
  64. Dambach D, Smith C, Lewis R, et al. Morphologic, immunohistochemical, and ultrastructural characterization of a distinctive renal lesion in dogs putatively associated with Borrelia burgdorferi infection: 49 cases (1987–1992). Vet Pathol 1997;34:85–96
  65. Borys MA, Kass PH, Mohr FC, et al. Differences in clinicopathologic variables between Borrelia C6 antigen seroreactive and Borrelia C6 seronegative glomerulopathy in dogs. Vet Intern Med 2019;33:2096–104.
  66. Purswell EK, Lashnits EW, Breitschwerdt EB, et al. A retrospective study of vector-borne disease prevalence in dogs with proteinuria: Southeastern United States. J Vet Intern Medicine 2020;34:742–53.
  67. Conlon JA, Mather TN, Tanner P, Gallo G, Jacobson RH. Efficacy of a nonadjuvanted, outer surface protein A, recombinant vaccine in dogs after challenge by ticks naturally infected with Borrelia burgdorferi. Vet Ther. 2000;1(2):96–107.
  68. Grosenbaugh DA, De Luca K, Durand PY, et al. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters. BMC Vet Res. 2018;14(1):312.
  69. Marconi RT, Garcia-Tapia D, Hoevers J, et al. VANGUARD (R) crLyme: A next generation Lyme disease vaccine that prevents B. burgdorferi infection in dogs. Vaccine X 2020;6:100079.
  70. Camire AC, Hatke AL, King VL, et al. Comparative analysis of antibody responses to outer surface protein (Osp)A and OspC in dogs vaccinated with Lyme disease vaccines. Vet J 2021;273:105676.
  71. Stillman BA, Thatcher B, Beall MJ, et al. Borrelia burgdorferi antibody test results in dogs administered 4 different vaccines. Top Companion Anim Med 2019;37:100358.
  72. Moroff S, Woodruff C, Woodring T, et al. Multiple antigen target approach using the Accuplex4 BioCD system to detect Borrelia burgdorferi antibodies in experimentally infected and vaccinated dogs. J Vet Diagn Invest 2015;27:581–8.
  73. Marques AR, Martin DS, Philipp MT. Evaluation of the C6 peptide enzyme-linked immunosorbent assay for individuals vaccinated with the recombinant OspA vaccine. J ClinMicrobiol 2002;40:2591–3.
  74. Ellis JA. How well do vaccines for Bordetella bronchiseptica work in dogs? A critical review of the literature 1977-2014. Vet J 2015;204:5–16.
  75. Scott-Garrad MM, Chiang Y-W, David F. Comparative onset of immunity of oral and intranasal vaccines against challenge with Bordetella bronchiseptica. Vet Rec Open 2018;5e000285.
  76. Ellis JA, Gow SP, Waldner CL, et al. Comparative efficacy of intranasal and oral vaccines against Bordetella bronchiseptica in dogs. Vet J 2016; 212:71–7.
  77. Ellis JA. Canine IgA and IgA deficiency: implications for immunization against respiratory pathogens. Can Vet J 2019;60:1305–11.
  78. Karkani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. Vaccine 2016;34:413–23.
  79. McDermott MR, Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tisssues. J Immunol 1979;122:1892–8.
  80. Moldoveanu Z, Russell MW, Wu HY, et al. Compartmentalization within the common mucosal immune system. In: Mestecky J, Russell MW, Jackson S, et al., eds. Advances in mucosal immunology. advances in experimental medicine and biology. Vol. 371. Boston: Springer; 1995: 97–101.
  81. Wu HY, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunologic Res 1997;16:187–201.
  82. Czerkinsky C, Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. In: Kozlowski P, ed. Mucosal vaccines. current topics in microbiology and immunology. Vol. 354. Berlin, Heidelberg: Springer; 2010:1–18.
  83. Brandgzaeg P. Potential of nasopharynx-associated lymphoid tissue for vaccine responses in airways. Am J Respir Crit Care 2011;183:1595–604.
  84. Feunou PF, Kammoun H, Debrie AS, et al. Heterologous prime-boost immunization with live attenuated B. pertussis vaccine in mice. Vaccine 2014;32:4281–8.
  85. He Q, Mao Q, An C, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect 2021;10(1):629–37.
  86. Ellis JA, Haines DM, West KH, et al. Effect of vaccination on experimental infection with Bordetella bronchiseptica in dogs. J Am Vet Med Assoc 2001;218:367–75.
  87. Ellis JA, Gow SP, Lee LB, et al. Comparative efficacy of intranasal and injectable vaccines in stimulating Bordetella bronchiseptica-reactive anamnestic antibody responses in household dogs. Can Vet J 2017;58: 809–15.
  88. Joffe DJ, Lelewski R, Weese JS, et al. Factors associated with development of canine infectious respiratory disease complex (CIRDC) in dogs in 5 Canadian small animal clinics. Can Vet J 2016:57:46–51.
  89. Maboni G, Seguel M, Lorton A, et al. Canine infectious respiratory disease: new insights into the etiology and epidemiology of associated pathogens. PLoS One 2019;14(4):e0215817.
  90. Toshach K, Jackson MW, Dubielzig RR. Hepatocellular necrosis associated with subcutaneous injection of an intranasal Bordetella bronchiseptica-canine parainfluenza vaccine. J Am Anim Hosp Assoc 1997;33:126–8.
  91. Ellis JA, Krakowka GS. A review of canine parainfluenza virus infection in dogs. J Am Vet Med Assoc 2012;240:273–84.
  92. Hainer N, Velineni S, Bowers A, et al. Oral vaccination of dogs with a monovalent live-avirulent vaccine confers 1 year of immunity against Bordetella bronchiseptica challenge. Vet J 2021;278:105775.
  93. Bemis DA, Greisen HA, Appel MJG. Pathogenesis of canine bordetellosis. J Infect Dis 1977;135:753–62.
  94. Ellis JA. Another look at the “dismal science” and Jenner’s experiment. Vet Clin North Am Small Anim Pract 2018; 48:243-255.
  95. Parrish CR, Voorhees IEH. H3N8 and H3N2 canine influenza viruses: understanding these new viruses in dogs. Vet Clin North Am Small Anim Pract 2019;49:643–9.
  96. Monto AS, Malosh RE, Petrie JG, et al. The doctrine of original antigenic sin: separating good from evil. J Infect Dis 2017;215:1782–8.
  97. Leonard MJ, Bresee C, Cruikshank A. Effects of the canine rattlesnake vaccine in moderate to severe cases of canine crotalid envenomation. Vet Med (Aukl) 2014;5:153–8.
  98. Witsil AJ, Wells RJ, Woods C, et al. 272 cases of rattlesnake envenomation in dogs: demographics and treatment including safety of F(ab’)2 antivenom use in 236 patients. Toxicon 2015;105:19–26.
  99.  Petras KE, Wells RJ, Pronko J. Suspected anaphylaxis and lack of clinical protection associated with envenomation in two dogs vaccinated with Crotalus atrox toxoid. Toxicon 2018;142:30–3.
  100. Cates CC, Valore EV, Couto MA, et al. Comparison of the protective effect of a commercially available western diamondback rattlesnake toxoid vaccine for dogs against envenomation of mice with western diamondback rattlesnake (Crotalus atrox), northern Pacific rattlesnake (Crotalus oreganus oreganus), and southern Pacific rattlesnake (Crotalus oreganus helleri) venom. Am J Vet Res 2015;76:272–9.
  101. Chippaux JP, Williams V, White J. Snake venom variability: methods of study, results and interpretation. Toxicon 1991;29:1279–303.
  102. Lechner ES, Crawford PC, Levy JK, et al. Prevalence of protective antibody titers for canine distemper virus and canine parvovirus in dogs entering a Florida animal shelter. J Am Vet Med Assoc 2010;236:1317–21.
  103. Litster A, Nichols J, Volpe A. Prevalence of positive antibody test results for canine parvovirus (CPV) and canine distemper virus (CDV) and response to modified live vaccination against CPV and CDV in dogs entering animal shelters. Vet Microbiol 2012;157:86–90.
  104. Spindel ME, Krecic MR, Slater MR, et al. Evaluation of a community’s risk for canine parvovirus and distemper using antibody testing and GIS mapping of animal shelter intakes. J Appl Anim Welf Sci 2018;21: 362–74.
  105. Gore T, Headley M, Laris R, et al. Intranasal kennel cough vaccine protecting dogs from experimental Bordetella bronchiseptica. Vet Rec 2005; 156:482–3.
  106. Kontor E, Wegrzyn R, Goodnow R. Canine infectious tracheobronchitis: effects of an intranasal live canine parainfluenza-Bordetella bronchiseptica vaccine on viral shedding and clinical tracheobronchitis (kennel cough). Am J Vet Res 1981;42:1694–8.
  107. Miller L, Zawistowski S, eds. Shelter medicine for veterinarians and staff. 2nd ed. Ames (IA): Wiley-Blackwell; 2013.
  108. Miller L, Hurley K, eds. Infectious disease management in animal shelters. Ames (IA): Wiley-Blackwell; 2009.
  109. Andrukonis A, Brown KM, Hall NJ, et al. Intake vaccinations reduced signs of canine respiratory disease during an outbreak at an animal shelter. Front Vet Sci 20921;8:627580.
  110. Newbury S, Blinn MK, Bushby PA, et al. Guidelines for standards of care in animal shelters. Corning (NY): Association of Shelter Veterinarians; 2010.
  111. World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO Technical Report Series 1004; 2017.
  112. Coyne MJ, Burr JHH, Yule TD, et al. Duration of immunity in dogs after vaccination or naturally acquired infection. Vet Rec 2001;149:509–15.
  113. Appel M, Robson DS. A microneutralization test for canine distemper virus. Am J Vet Res 1973;34:1459–63.
  114. Carmichael LE, Joubert JC, Pollock RV. Hemagglutination by canine parvovirus: serologic studies and diagnostic applications. Am J Vet Res 1980;41:784–91.
  115. Waner T, Naveh A, Wudovsky I, et al. Assessment of maternal antibody decay and response to canine parvovirus vaccination using an enzyme-linked immunosorbent assay. J Vet Diag Invest 1996;8:426–32.
  116. Waner T, Naveh A, Schwarz Ben Meir N, et al. Assessment of immunization response to canine distemper virus vaccination in puppies using a clinic-based enzyme-linked immunosorbent assay. Vet J 1998;155:171–5.
  117. Gray LK, Crawford PC, Levy JK, et al. Comparison of two assays for detection of antibodies against canine parvovirus and canine distemper virus in dogs admitted to a Florida animal shelter. J Am Vet Med Assoc 2012;240:1084–7.
  118. Litster A, Nichols J, Volpe A. Prevalence of positive antibody test results for canine parvovirus (CPV) and canine distemper virus (CDV) and response to modified live vaccination against CPV and CDV in dogs entering animal shelters. Vet Microbiol 2012;157:86–90.
  119. Rothman KJ. Causes. Am J Epidemiol 1976;104:587–92.
  120. Valli JL. Suspected adverse reactions to vaccination in Canadian dogs and cats. Can Vet J 2015;56:1090–3.
  121. Pawelec G. Age and immunity: what is “immunosenescence”? Exp Gerontol 2018;105:4–9.
  122. Siegrist CA. Mechanisms underlying adverse reactions to vaccines. J Comp Pathol 2007;137 suppl 1:S46–50.
  123. Gershwin LJ. Adverse reactions to vaccination: from anaphylaxis to autoimmunity. Vet Clin North Am Small Anim Pract 2018;48:279–90.
  124. Moon A, Veir J. Vaccination and associated adverse events in dogs previously treated for primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2019;55:29–34.
  125. Stone CA Jr, Rukasin CRF, Beachkofsky TM, et al. Immune-mediated adverse reactions to vaccines. Br J Clin Pharmacol 2019;85:2694–706.
  126. Moore GE, HogenEsch H. Adverse vaccinal events in dogs and cats. Vet Clin North Am Small Anim Pract 2010;40:393–407.
  127. Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009;10:837–52.
  128. Whitaker JA, Ovsyannikova IG, Poland GA. Adversomics: a new paradigm for vaccine safety and design. Expert Rev Vaccines 2015;14:935–47.
  129. Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine 2018;36:5350–7.
  130. Kang SM, Compans RW. Host responses from innate to adaptive immunity after vaccination: molecular and cellular events. Mol Cells 2009;27:5–14.
  131. Ohmori K, Masuda K, Maeda S, et al. IgE reactivity to vaccine components in dogs that developed immediate-type allergic reactions after vaccination. Vet Immunol Immunopathol 2005;104:249–56.
  132. Moore GE, Franco J, Aryal U, et al. Proteomic analysis of canine vaccines (abstr). J Vet InternMed 2020;34:2913.
  133. Nara PL, Krakowka S, Powers TE. Effects of prednisolone on the development of immune responses to canine distemper virus in beagle pups. Am J Vet Res 1979;40:1742–7.
  134. Blancou J, Milward F, Toma B, et al. Vaccination against rabies in carnivores treated with corticoids. Rec Méd Vét 1981;157:631–57.
  135. Centers for Disease Control and Prevention. Vaccine Storage and Handling Resources. Available at: https://www.cdc.gov/vaccines/hcp/admin/ storage/index.html. Accessed June 27, 2022.
  136. Centers for Disease Control and Prevention. 2022 Vaccine Storage and Handling. Available at: https://www2a.cdc.gov/nip/isd/ycts/mod1/ courses/sh/index.html. Accessed June 27, 2022.
  137. Erdman MM, Clough NE, Hauer PJ. Review of updated regulations and product license in categories for veterinary vaccines in the United States. J Am VetMed Assoc 2020;257:1142–7.
  138. USDA. Product Summaries. Available at: https://www.aphis.usda.gov/ aphis/ourfocus/animalhealth/veterinary-biologics/product-summaries. Accessed June 27, 2022.
  139. USDA. Veterinary Biologics. Available at: https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/veterinary-biologics. Accessed June 27, 2022.
  140. USDA. Common Questions About Veterinary Biologics. Available at: https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/veterinarybiologics/ct_vb_pel_faqs. Accessed June 27, 2022.
  141. Canadian Centre for Veterinary Biologics. The Regulation of Veterinary Biologics in Canada – Overview. Available at: https:// inspection.canada.ca/animal-health/veterinary-biologics/guidelinesforms/ 4-10e/eng/1328215080021/1328215153251. Accessed June 27, 2022.
Elanco
Merck Animal Health
Zoetis
Boehringer Ingelheim

Select the items you want to download